{"phase":{"coding":[{"code":"phase-3","display":"Phase 3","system":"http://terminology.hl7.org/CodeSystem/research-study-phase","version":"4.0.1"}],"text":"Research Study Phase"},"identifier":[{"assigner":{"display":"Reference to primary assigner","type":"Organization"},"use":"official","value":"INDISPONIBLE"},{"assigner":{"display":"Reference to secondary assigner","reference":"Organization/ctis","type":"Organization"},"use":"secondary","value":"2022-500014-26-00"}],"sponsor":{"display":"Reference to primary sponsor","reference":"Organization/2022-500014-26-00-primary-sponsor","type":"Organization"},"extension":[{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-secondary-sponsor","valueReference":{"display":"Reference to secondary sponsor","reference":"Organization/2022-500014-26-00-secondary-sponsor","type":"Organization"}},{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-therapeutic-area","valueString":"Diseases [C] - Neoplasms [C04]"},{"extension":[{"url":"labelValue","valueString":"INDISPONIBLE"},{"url":"labelType","valueCodeableConcept":{"coding":[{"code":"human-use","display":"Human use","system":"http://hl7.org/fhir/title-type","version":"5.0.0"}],"text":"Label Type"}}],"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-label"},{"extension":[{"url":"labelValue","valueString":"INDISPONIBLE"},{"url":"labelType","valueCodeableConcept":{"coding":[{"code":"acronym","display":"Acronym","system":"http://hl7.org/fhir/title-type","version":"5.0.0"}],"text":"Label Type"}}],"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-label"},{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-recruitment-period","valuePeriod":{"start":"2022-06-30T00:00:00.000Z"}},{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-review-date","valueInstant":"2023-04-12T00:00:00.000Z"}],"description":"INDISPONIBLE","title":"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER","enrollment":[{"display":"Reference to group detailing study characteristics","reference":"#2022-500014-26-00-enrollment-group-id","type":"Group"}],"condition":[{"coding":[{"display":"Locally-Advanced or Metastatic breast cancer (MBC)"}],"text":"Disease Condition"},{"coding":[{"code":"10070575","display":"MedDRA","system":"http://terminology.hl7.org/CodeSystem/mdr","version":"2.0.1"},{"code":"10065430","display":"MedDRA","system":"http://terminology.hl7.org/CodeSystem/mdr","version":"2.0.1"}],"text":"MedDRA Condition"}],"contained":[{"actual":true,"characteristic":[{"exclude":false,"valueCodeableConcept":{"coding":[{"code":"male","display":"Male","system":"http://hl7.org/fhir/administrative-gender","version":"5.0.0"},{"code":"female","display":"Female","system":"http://hl7.org/fhir/administrative-gender","version":"5.0.0"}],"text":"Genders"}},{"exclude":false,"valueRange":{"low":{"comparator":">=","unit":"years","value":65}}},{"exclude":false,"valueRange":{"high":{"comparator":"<=","unit":"years","value":64},"low":{"comparator":">=","unit":"years","value":18}}},{"exclude":false,"valueCodeableConcept":{"coding":[{"display":"Données non disponible"}],"text":"Research Study Group Category"}},{"exclude":false,"valueCodeableConcept":{"coding":[{"display":"Femmes en âge de procréer n’utilisant pas de contraception"},{"display":"Femmes en âge de procréer utilisant une méthode de contraception"}],"text":"Study Population"}},{"exclude":false,"valueCodeableConcept":{"coding":[{"display":"INDISPONIBLE"}],"text":"Study Inclusion Criteria"}},{"exclude":true,"valueCodeableConcept":{"coding":[{"display":"INDISPONIBLE"}],"text":"Study Exclusion Criteria"}}],"id":"2022-500014-26-00-enrollment-group-id","quantity":21,"type":"person","resourceType":"Group"}],"site":[{"display":"Reference to site","reference":"Location/0-ctis-site","type":"Location"}],"meta":{"lastUpdated":"2023-04-12T00:00:00.000Z","profile":["https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-researchstudy"]},"contact":[{"name":"Head of EU Trial Information Support Line-TISL, Switzerland","telecom":[{"system":"phone","use":"work","value":"0041616881111"},{"system":"email","use":"work","value":"global.rochegenentechtrials@roche.com"}]},{"extension":[{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type","valueCodeableConcept":{"coding":[{"code":"SCI","display":"Scientifique / Scientific","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system","version":"0.1.0"}],"text":"Contact Type"}}],"name":"INDISPONIBLE INDISPONIBLE","telecom":[{"system":"phone","use":"work","value":"INDISPONIBLE"},{"system":"email","use":"work","value":"INDISPONIBLE"}]},{"extension":[{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type","valueCodeableConcept":{"coding":[{"code":"PUB","display":"Publique / Public","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system","version":"0.1.0"}],"text":"Contact Type"}}],"name":"INDISPONIBLE INDISPONIBLE","telecom":[{"system":"phone","use":"work","value":"INDISPONIBLE"},{"system":"email","use":"work","value":"INDISPONIBLE"}]}],"location":[{"coding":[{"code":"BE","display":"Belgium","system":"urn:iso:std:iso:3166","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"DE","display":"Germany","system":"urn:iso:std:iso:3166","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"ES","display":"Spain","system":"urn:iso:std:iso:3166","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"FR","display":"France","system":"urn:iso:std:iso:3166","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"HU","display":"Hungary","system":"urn:iso:std:iso:3166","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"IT","display":"Italy","system":"urn:iso:std:iso:3166","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"PL","display":"Poland","system":"urn:iso:std:iso:3166","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"PT","display":"Portugal","system":"urn:iso:std:iso:3166","version":"4.0.1"}],"text":"Countries of recruitment"}],"id":"2022-500014-26-00","category":[{"coding":[{"display":"REG536"}],"text":"Regulation Code"}],"resourceType":"ResearchStudy","status":"active"}